|
| Number | Study | Application method | Conditions | Phase | Trial institution/sponsor and country | NCT number and duration period |
|
| (1) | Adipose derived Regenerative Cellular Therapy of Chronic Wounds | Injections to the wound | Venous ulcer, diabetic foot, pressure ulcer | II | Tower Outpatient Clinic, Los Angeles, California, USA | NCT02092870
2013–2015 |
| (2) | ADSCs and Pressure Ulcers | Injections (stromal vascular fraction) to rim around the venous stasis of the wound | Chronic venous stasis wounds | I | Sanford Plastic and Reconstructive Surgery Clinic, Sioux Falls, USA | NCT02961699
2017–2020 |
| (3) | ADSCs and Pressure Ulcers | Injected into a fibrin sealant applicator and applied to the wound | Pressure ulcer | I | Mayo Clinic, Florida, USA | NCT02375802
2015–2017 |
| (4) | Safety of Adipose-Derived Stem Cell Stromal Vascular Fraction | Injections with or without unprocessed autologous fat (fresh or cryopreserved) | Abnormally healing wounds, scars, and soft tissue defects | I | AdiSave Inc., Canada | NCT02590042
2015–2019 |
| (5) | Assessment of the Efficacy and Tolerance of Sub-cutaneous Re-injection of Autologous Adipose-derived REGEnerative Cellsin the Local Treatment of Neuropathic Diabetic Foot ulcERs (REGENDER) | Injections to the wound | Diabetic foot ulcer | II | Assistance Publique Hopitaux De Marseille, France | NCT02866565
2017–2019 |
| (6) | Treatment of Hypertensive Leg Ulcer by Adipose Tissue Grafting | Adipose tissue grafting (lipofilling) | Hypertensive leg ulcer | I | University Hospital, Caen, France | NCT01932021
2013–2014 |
| (7) | Safety of ALLO-ASC-DFU in the Patients with Diabetic Foot Ulcers | ALLO-ASC-DFU | Diabetic foot ulcer | I | Asan Medical Center, Seoul, South Korea | NCT02394886
2014–2015 |
| (8) | The Role of Lipoaspirate Injection in the Treatment of Diabetic Lower Extremity Wounds and Venous Stasis Ulcers | Injection of lipoaspirate | Diabetic wounds, venous stasis wounds | — | Washington DC Veterans Affairs Medical Center, USA | NCT00815217
2009–2010 |
| (9) | Allogeneic ADSCs and Platelet-Poor Plasma Fibrin Hydrogel to Treat the Patients With Burn Wounds | Applied by surface application over perforated (1 : 3) autologous skin graft | Second- or third-degree burns | I, II | The Kyiv City Clinical Hospital, Ukraine | NCT03113747
2015–2018 |
| (10) | Safety of ADSCs Stromal Vascular Fraction | Injections (stromal vascular fraction) to the wound fresh or cryopreserved autologous fat | Abnormally healing wounds, scars, and soft tissue defects | I | Forest Hill Institute of Aesthetic Plastic Surgery, Toronto, Ontario, Canada | NCT02590042
2015–2019 |
| (11) | Child’s Adipose Cells: Capacity of Tissue Regeneration | Adipose tissue sample in children < 10 y. | A nude mouse model of skin burn | — | CHU de Toulouse-Purpan, Tolouse, France | NCT02779205
2015–2017 |
| (12) | A Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Deep Second-degree Burn Wound | A hydrogel sheet containing allogenic ASC | Deep second-degree burn wound patients | I | Hallym University of Medical Center, Seoul, Republic of Korea | NCT02394873
2015 |
| (13) | ADSCs for the Treatment of Perianal Fistula in Crohn Disease: A Pilot Study (ASPEFIC1) | ADSC injection | Perianal fistula Crohn’s disease | II | Papa Giovanni XXIII Hospital, Italy | NCT02403232
2014–2018 |
| (14) | Autologous Cultured Adipose-Derived Stem Cells (ANTG-ASC) on Complex and Crohn’s Fistula | ADSC injection | Perianal fistula
Crohn’s disease | II | Seoul National University Hospital, Republic of Korea | NCT01314092
2011–2016 |
| (15) | Adipose-Derived Stem Cells to Treat Complex Perianal Fistulas | ADSC injection and dressing with fibrin glue | Perianal fistulas | I | General Surgery Department, Hospital Universitario La Paz, Spain | NCT01020825
2009–2011 |
|
